SON-1010 is under clinical development by Sonnet BioTherapeutics and currently in Phase I for Mesenchymal Tumor. According to GlobalData, Phase I drugs for Mesenchymal Tumor have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SON-1010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SON-1010 is under development for the treatment of mesenchymal tumor, solid tumors including non-small cell lung cancer, platinum-resistant epithelial ovarian cancer, fallopian tube cancer and peritoneal cancer, head and neck cancer, endometrial sarcoma, melanoma and platinum-resistant ovarian cancer . The drug candidate comprises of albumin targeting single chain variable fragment (ScFv), an albumin binding domain fused to interleukin 12. The therapeutic candidate is developed based on single domain antibody fragment platform (ScFv and VhH) technology and Fully Human Albumin Binding (FHAB) technology. It acts by targeting IL12 receptor. The drug candidate is administered through subcutaneous route.
The drug candidate was under for the treatment of influenza A virus, H1N1 subtype infections.
Sonnet BioTherapeutics overview
Sonnet BioTherapeutics (Sonnet), formerly Chanticleer Holdings Inc, is an oncology-biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific, bifunctional action. The company’s pipeline program includes Son-1010(IL12-FHAB), Son-1210(IL12-FHAB), Son-1210(IL12-FHAB-1L15), Son-1410(IL18-FHAB-1L12), Son-3015(Anti-1L6-FHAB-Anti-TGFB), SON-080(Low-dose IL- 6). Its pipeline candidates treat solid tumors, platinum-resistant ovarian cancer, solid tumors, melanoma renal cancers, tumor and bone metastases, chemotherapy-induced peripheral neurotherapy and diabetic peripheral neuropathy. Sonnet harnesses its proprietary FHAB (Fully Human Albumin Binding) technology to discover biologic drugs with single or bispecific action for antiviral applications. Its FHAB platform also serves as a plug-and-play construct for enhancing the potential of a broad range of large molecule therapeutic classes, including peptides, antibodies, cytokines, and vaccines. Sonnet is headquartered in Princeton, New Jersey, the US.
For a complete picture of SON-1010’s drug-specific PTSR and LoA scores, buy the report here.